循证心理治疗下PTSD诊断丧失率的系统综述与荟萃分析
该系统综述与荟萃分析纳入34项随机临床试验共3208名参与者,评估创伤聚焦心理治疗后不再符合PTSD诊断标准的比例。非军人/退伍军人样本的诊断丧失点估计为65%至86%,军人/退伍军人样本在认知加工疗法和延长暴露中为44%至50%。
要点
- 非军人/退伍军人样本创伤聚焦治疗后诊断丧失点估计为65%至86%。
- 军人/退伍军人样本在认知加工疗法和延长暴露中诊断丧失为44%至50%。
- 眼动脱敏与再加工探索性分析显示最高诊断丧失比例但异质性大且无美国军人研究。
核心结论
- 该荟萃分析汇总了每种心理治疗的PTSD诊断丧失概率,为讨论治疗潜在获益提供直观数据。
- 军人/退伍军人样本在认知加工疗法和延长暴露中诊断丧失比例低于非军人/退伍军人样本。
研究设计与样本
- 系统综述与荟萃分析,数据来自美国国家PTSD中心维护的PTSD Repository,检索1988年1月起发表的随机临床试验。
- 纳入34项随机临床试验,共3208名经 validated 评估确诊DSM-IV/DSM-5 PTSD的成人参与者,心理治疗为单一治疗且PTSD为主要治疗目标。
- 采用混合效应逻辑回归模型估计诊断丧失,并将军人/退伍军人身份和性别作为协变量纳入。
主要发现
- 非军人/退伍军人样本中创伤聚焦治疗的诊断丧失点估计范围为65%至86%。
- 军人/退伍军人样本在认知加工疗法和延长暴露研究中的诊断丧失比例范围为44%至50%,低于非军人/退伍军人样本。
- 军人/退伍军人身份与性别两个协变量存在大量重叠。
- 探索性分析显示眼动脱敏与再加工诊断丧失比例最高,但异质性大,且无研究以军人/退伍军人为焦点或在美国开展。
- 所有创伤聚焦治疗估计的95%置信区间部分重叠。
关键数值与推荐
- 纳入标准要求PTSD为主要治疗目标、心理治疗为单一治疗、报告治疗后不再符合PTSD诊断标准的参与者人数。
- 主要结局为经 validated 工具评估的治疗后不再符合PTSD诊断标准的参与者比例。
临床怎么用
- 诊断丧失数据可用于启动治疗时讨论潜在获益,或讨论治疗进展中的潜在障碍。
- 临床讨论预后时应考虑军人/退伍军人身份与性别的重叠影响。
局限性
- 眼动脱敏与再加工分析为探索性且异质性大,无军人/退伍军人焦点研究或美国开展的研究。
- 所有创伤聚焦治疗估计的95%置信区间部分重叠。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: In recent decades, evidence-based psychotherapies to treat posttraumatic stress disorder (PTSD) have been developed with robust evidence bases. However, efficacy observed in clinical trials is not always directly applicable to clinical practice. OBJECTIVE: To estimate the percentage of patients in both military and veteran (hereafter milvet) and nonmilvet populations that lose their PTSD diagnosis after treatment. DATA SOURCES: We used the PTSD Repository to identify studies with adults with a DSM-IV/DSM-5 PTSD diagnosis based on a validated assessment. The repository, maintained by the US National Center for PTSD, is continually updated with randomized clinical trials and includes studies published from January 1988 on. STUDY SELECTION: For eligibility, PTSD had to be the primary treatment target, with psychotherapy applied as monotreatment. Eligible studies reported the number of participants who did not meet diagnostic criteria for PTSD posttreatment. When this review was initiated (October 2023), the repository contained 496 unique studies. Data analysis was completed from October 2023 to June 2024. DATA EXTRACTION AND SYNTHESIS: The repository follows Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guidelines and uses Cochrane Risk of Bias 2.0. We used mixed-effects logistic regression models to estimate diagnosis loss and incorporated milvet status and sex as covariates. MAIN OUTCOMES AND MEASURES: The primary outcome was the proportion of participants who no longer met criteria for a diagnosis of PTSD posttreatment as assessed by a validated instrument. RESULTS: We included 34 randomized clinical trials (N = 3208 participants). Point estimates of diagnosis loss across trauma-focused treatments for nonmilvet samples ranged from 65% to 86%. Milvet samples had lower proportions of diagnosis loss in studies of cognitive processing therapy and prolonged exposure compared to nonmilvet samples, ranging from 44% to 50%. There was substantial overlap between the covariates of milvet status and sex. An exploratory analysis identified eye movement desensitization and reprocessing as having the highest proportion of diagnosis loss, but there was substantial heterogeneity, and none of the studies were milvet-focused or conducted in the US. Also, 95% confidence intervals partially overlapped for all trauma-focused treatment estimates. CONCLUSIONS AND RELEVANCE: This systematic review and meta-analysis contributes to the substantial literature on psychotherapeutic treatments for PTSD by meta-analyzing the probabilities of diagnosis loss for each psychotherapy. Diagnosis loss data are a relatively straightforward way to discuss potential benefits when initiating a therapy or when discussing potential barriers to progress in treatment.
引用
- Milligan T, Smolenski D, Lara-Ruiz J, et al. Loss of PTSD Diagnosis in Response to Evidence-Based Treatments: A Systematic Review and Meta-Analysis. JAMA Psychiatry. 2025. PMID: 40397424. doi:10.1001/jamapsychiatry.2025.0695
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。